Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence with Treatment in Overactive Bladder (OAB) Patients Prescribed BetmigaTM - A Multicenter Non-interventional Post Authorisation Study (PAS)

Trial Profile

Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence with Treatment in Overactive Bladder (OAB) Patients Prescribed BetmigaTM - A Multicenter Non-interventional Post Authorisation Study (PAS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Mirabegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms BELIEVE
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 16 Sep 2016 Interim results assessing quality of life and persistence in overactive bladder after six months of observation (n=396) presented at the 46th Annual Meeting of the International Continence Society.
    • 31 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top